ERBB2 and breast cancer: As expected, cancer-related pathways in each model were downregulated by treatment; e.g. Kras was downregulated by aCD40 + aPD-1 in the MT4 model, and Erbb2 (Her2) was downregulated in the NDL breast cancer model with both the ablation + aPD-1 and aCD40 + aPD-1 treatments.